StreetAlpha.app
Home › Stocks › XENE

Xenon Pharmaceuticals Inc. (XENE)

Healthcare
$38.78
▼ −1.22%
LAST CLOSE · NOV 17

Xenon Pharmaceuticals develops investigational drugs for neurological and psychiatric conditions, led by azetukalner for epilepsy and depression. It last closed at $38.78 on Nov 17, down 1.22% on the day. XENE last reported earnings on Mon, Nov 9, 2026. The average 12-month price target from 7 analysts is $65.43 (+68.7% from the last close), with a high of $90.00 and a low of $46.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (6 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in XENE, 100% of them bullish and 0% bearish. In the past 30 days there were 1 dark pool print totaling $728K, the largest $728K.

AI Auto Pilots
Is XENE in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$428.7M
EPS (diluted)
−$4.69
Free cash flow
−$357.1M
Valuation
Market cap
$3.8B
98.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$82.6M
At Sep 30
Shareholder equity
$1.1B
Shares outstanding
98.3M
At Nov 5
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $18.4M$18.4MFY2021FY2022: $9.4M$9.4MFY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $7.5M$7.5MFY2025

From XENE's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · After the close (AMC)
Reported EPS
-$1.15
vs -$1.14 est. · inline
Year-ago EPS
-$1.15
Same quarter last year
Options-implied move
±9.2%
Priced in before that report
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
6 Buy1 Hold0 Sell
Each firm's latest rating on XENE in the past 90 days
Average 12-month target
$65.43
▲ 68.7% upside

Based on 7 analysts who set a price target on XENE in the past 90 days. The average target is $65.43, with a high of $90.00 and a low of $46.00, compared with the last close of $38.78.

Low $46.00Avg $65.43High $90.00
Blue marker: last close $38.78
Highest target$90.00
Average target$65.43
Lowest target$46.00
Latest rating changes
GuggenheimAssumed coverage
Oct 6Buy$73
RBC CapitalTarget lowered
Sep 18Buy$81 → $70
WedbushMaintained
Sep 18Buy$55
Wells FargoMaintained
Sep 18Buy$64
Deutsche BankDowngrade
Sep 18Hold$46
DateFirmActionRatingPrice target
Oct 6GuggenheimAssumed coverageBuy$73
Sep 18RBC CapitalTarget loweredBuy$81 → $70
Sep 18WedbushMaintainedBuy$55
Sep 18Wells FargoMaintainedBuy$64
Sep 18Deutsche BankDowngradeHold$46
Loading…

Technical Analysis

XENE · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock sits between its 20 and 50 day averages. It is 35% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the 20 day average at $38.31, and the nearest resistance the Pivot at $38.83.

Short trendBullish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 3.8%/day
Key levels
$72.6652 week high+87.4%
$52.25200 day average+34.7%
$51.92100 day average+33.9%
$40.3050 day average+3.9%
$39.92Swing high (Oct 1)+2.9%
$39.42Pivot R1+1.7%
$38.83Pivot+0.1%
$38.78Last close
$38.3120 day average−1.2%
$38.18Pivot S1−1.5%
$37.15Swing low (Nov 6)−4.2%
$33.3852 week low−13.9%
Indicators
RSI (14)47.72Middle of its rangeNeutral
MACD0.16Above its signal lineBullish
Stochastic57.3Middle of its rangeNeutral
ADX (14)21.3Weak trend
Williams %R-59.9Oversold below −80, overbought above −20Neutral
CCI (20)23.4Oversold below −100, overbought above 100Neutral
Rate of change+1.4%Change over 10 sessionsBullish
ATR (14)$1.49Typical daily range, 3.8% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for XENE

What happened before

See how XENE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow XENE usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How XENE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 25 – Sep 25
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$728K
Largest print
$728K
Loading…

XENE Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●158 buying vs 156 selling
  • ●Held by funds +0.1 pts
  • ▼Funds holding -31
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding286317−9.8%
In funds' top 10612−50.0%
Held by funds103.1%103.0%+0.1 pts
New / increased34 / 12447 / 126−8.7%
Reduced / sold out95 / 6186 / 23+43.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See XENE institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether XENE is in one of them and how their past XENE trades turned out.

XENE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered XENE in an article yet. Here's the latest on the wider market.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals is a biopharmaceutical company based in Burnaby, Canada, that focuses on drugs for neurological and psychiatric conditions. Its lead investigational medicine, azetukalner, is in late-stage trials for epilepsy, major depressive disorder and bipolar depression. The company also has earlier-stage programs aimed at pain and other conditions. Its intended customers are patients with these disorders, and it may commercialize its candidates alone or with partners.

Headquarters
Burnaby
Founded
1996